We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 29, 2022

Copanlisib in Patients With Tumors With PIK3CA Mutations

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
J. Clin. Oncol 2022 May 10;40(14)1552-1561, S Damodaran, F Zhao, DA Deming, EP Mitchell, JJ Wright, RJ Gray, V Wang, LM McShane, LV Rubinstein, DR Patton, PM Williams, SR Hamilton, JM Suga, BA Conley, CL Arteaga, LN Harris, PJ O'Dwyer, AP Chen, KT Flaherty

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading